Biogen (MEX:BIIB) COGS-to-Revenue

: 0.27 (As of Mar. 2023)

View and export this data going back to 2013. Start your Free Trial

Biogen's Cost of Goods Sold for the three months ended in Mar. 2023 was MXN11,947 Mil. Its Revenue for the three months ended in Mar. 2023 was MXN44,396 Mil.

Biogen's COGS to Revenue for the three months ended in Mar. 2023 was 0.27.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Biogen's Gross Margin % for the three months ended in Mar. 2023 was 73.09%.

Biogen COGS-to-Revenue Historical Data

The historical data trend for Biogen's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

COGS-to-Revenue

0.14

0.13

0.19

0.22

Biogen Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
COGS-to-Revenue																0.30	0.19	0.19	0.22	0.27

Biogen COGS-to-Revenue Calculation

Biogen's COGS to Revenue for the fiscal year that ended in Dec. 2022 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	44417.737	/	198340.607
	=	0.22

Biogen's COGS to Revenue for the quarter that ended in Mar. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	11946.97	/	44395.575
	=	0.27

Biogen (MEX:BIIB) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Biogen's Gross Margin % for the three months ended in Mar. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	11946.97 / 44395.575
	=	73.09 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Biogen COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Biogen's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (MEX:BIIB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (MEX:BIIB) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

BIIB:USA IDP:Germany BIIB34:Brazil BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

http://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.